Hazard Ratios of Clinical Endpoints for the Japan EPA Lipid Intervention Study (JELIS). Superscript 1 and 2 indicate primary and secondary prevention endpoints, respectively [60]. ∗P < 0.05. Reprinted from The Lancet, 369, Yokoyama M, Origasa H, Matsuzaki M et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis, 1090–1098. Copyright 2007, with permission from Elsevier.